We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Abbott, Medtronic, Boston Scientific Corporation ... the market is segmented based on product type (drug-eluting stent (DES), ...

The ELEGANCE registry, which is focused on historically underrepresented minorities and women, analyzed endovascular treatment ...

The global non-vascular stents market is on the verge of significant expansion, expected to achieve a compound annual growth rate (CAGR) of 4.5% from 2022 to 2032. Valued at USD 1.21 billion in 2022, ...

The prospective, multicenter ROADSTER 3 postapproval trial is evaluating the safety and effectiveness of transcarotid artery re ...

The growth of the stent graft balloon catheter market is primarily driven by the increasing prevalence of cardiovascular ...

Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior ...

The RESTO (Morphological Parameters of In‐Stent Restenosis Assessed and Identified by OCT ... Offline analysis was performed with proprietary software (Aptivue A4, Abbott Vascular) after confirming ...

Endoscopy Sales Growth: 7% organically in Q3 2024. Boston Scientific Corp (NYSE:BSX) reported a 19% growth in operational sales and an 18% increase in organic sales for Q3 2024, exceeding their ...

Boston Scientific is keeping the ball rolling in ... That covers a 25.0% increase across the company’s cardiology and peripheral vascular divisions, which amounted to $2.731 billion, as well ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...